SCHEMBL6008038

SCHEMBL6008038

S=Cc1cccc2nc3ccccc3cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.55
ALDH1A1 P00352 4/20 0.55
HPGD P15428 4/20 0.55
KMT2A Q03164 4/20 0.55
RAB9A P51151 4/20 0.55
GLA P06280 3/20 0.55
GAA P10253 3/20 0.55
LMNA P02545 2/20 0.55
NPC1 O15118 1/20 0.55
POLB P06746 1/20 0.55
PTBP1 P26599 1/20 0.55
RCE1 Q9Y256 1/20 0.55
MAPT P10636 4/20 0.50
ACHE P22303 2/20 0.50
IDO1 P14902 1/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 1/20 0.41
ESR1 P03372 2/20 0.40
ESR2 Q92731 2/20 0.40
HTR3A P46098 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL738321 0.85 ALDH1A1 (0.55) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL30044538 0.85 ALDH1A1 (0.55) KDM4EALDH1A1HPGDKMT2ARAB9A
Hydrochloric Acid SCHEMBL9634743 0.84 ALDH1A1 (0.53) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL28369826 0.81 KDM4E (0.55) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL291404 0.81 ALDH1A1 (0.55) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL2448842 0.81 LMNA (0.55) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL4299906 0.80 ALDH1A1 (0.70) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL7644368 0.79 PDGFRB (0.53) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL7644364 0.79 PDGFRB (0.53) KDM4EALDH1A1HPGDKMT2ARAB9A
SCHEMBL30857473 0.76 ALDH1A1 (0.64) KDM4EALDH1A1HPGDKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 KDM4E 1370/4885ALDH1A1 228/4885HPGD 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.